Advertisement

Topics

First Patient Dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination With Opdivo® (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

13:00 EDT 13 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotechnology company focused on designing and developing viral-based immune-targeted therapies for the treatment of cancers and infectious diseases, today...

Other Sources for this Article

Transgene:
Lucie Larguier, +33 (0)3 88 27 91 04
Director Corporate Communications & IR
investorrelations@transgene.fr
or
Media contacts:
Citigate Dewe Rogerson
David Dible / Marine Perrier, + 44 (0)20 7638 9571
transgene@citigatedr.co.uk

NEXT ARTICLE

More From BioPortfolio on "First Patient Dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination With Opdivo® (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...